Search results for " Targeted therapy"

showing 10 items of 198 documents

Cardiovascular effects and molecular targets of resveratrol

2012

Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a polyphenol phytoalexin present in a variety of plant species and has been implicated to explain the health benefits of red wine. A wide range of health beneficial effects have been demonstrated for resveratrol in animal studies. In this review, we summarize the cardiovascular effects of resveratrol with emphasis on the molecular targets of the compound. In this regard, resveratrol stimulates endothelial production of nitric oxide, reduces oxidative stress, inhibits vascular inflammation and prevents platelet aggregation. In animal models of cardiovascular disease, resveratrol protects the heart from ischemia-reperfusion injury, reduces blo…

Cancer Researchmedicine.medical_specialtyPhysiologyClinical BiochemistryEstrogen receptorResveratrolPharmacologyNitric Oxidemedicine.disease_causeBiochemistryNitric oxidechemistry.chemical_compoundInternal medicineStilbenesmedicineAnimalsHumansMolecular Targeted TherapyProtein kinase AbiologySirtuin 1food and beveragesCardiovascular AgentsEndocrinologychemistryCardiovascular DiseasesResveratrolbiology.proteinProtein deacetylaseAnimal studiesOxidative stressNitric Oxide
researchProduct

Targeting cancer with peptide aptamers

2011

Renaud Seigneuric 1,2 , Jessica Gobbo 1,2 , Pierre Colas 3 , Carmen Garrido 1,2 1 Heat Shock Proteins and Cancer, INSERM, UMR 866 IFR 100, Faculty of Medicine, 7 Boulevard Jeanne D'Arc, 21000 Dijon, France 2 Universite de Bourgogne, Dijon, France 3 CNRS USR 3151, P2I2 Group, Station Biologique, Roscoff, Bretagne, France Received: June 22, 2011; Accepted: June 24, 2011; Published: June 24, 2011; Correspondence: Renaud Seigneuric, email: // // Abstract A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but al…

Cancer chemotherapyAptamermedicine.medical_treatmentRecombinant Fusion ProteinsPeptide Aptamersheat shock proteinAntineoplastic AgentsComputational biologyPharmacologyBiologyTargeted therapy03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansNanotechnologyMolecular Targeted TherapyHeat-Shock Proteins030304 developmental biologyCancer0303 health sciencesClinical Trials as TopicCanceraptamerAntineoplastic Protocolsmedicine.diseasetargeted therapypeptide3. Good healthOncology030220 oncology & carcinogenesisResearch PerspectivesAptamers PeptideOncotarget
researchProduct

MicroRNAs: Promising New Antiangiogenic Targets in Cancer

2014

[EN] MicroRNAs are one class of small, endogenous, non-coding RNAs that are approximately 22 nucleotides in length; they are very numerous, have been phylogenetically conserved, and involved in biological processes such as development, differentiation, cell proliferation, and apoptosis. MicroRNAs contribute to modulating the expression levels of specific proteins based on sequence complementarity with their target mRNA molecules and so they play a key role in both health and disease. Angiogenesis is the process of new blood vessel formation from preexisting ones, which is particularly relevant to cancer and its progression. Over the last few years, microRNAs have emerged as critical regulat…

Cell typeDOWN-REGULATIONArticle SubjectAngiogenesisHUMAN BREAST-CANCERMIR-200 FAMILYlcsh:MedicineAngiogenesis InhibitorsReview ArticleBiologyBioinformaticsGeneral Biochemistry Genetics and Molecular BiologyNUCLEAR EXPORTTUMOR ANGIOGENESISNeovascularizationMicroprocessor complexSMALL RNASDownregulation and upregulationNeoplasmsmicroRNAGene expressionmedicineAnimalsHumansMolecular Targeted TherapyPrecision MedicineIN-VIVOGENE-EXPRESSIONGeneral Immunology and MicrobiologyNeovascularization PathologicCell growthlcsh:RMICROBIOLOGIAGeneral MedicineMICROPROCESSOR COMPLEXMicroRNAsENDOTHELIAL GROWTH-FACTORCancer researchmedicine.symptom
researchProduct

Presenilin is the molecular target of acidic γ-secretase modulators in living cells.

2012

The intramembrane-cleaving protease γ-secretase catalyzes the last step in the generation of toxic amyloid-β (Aβ) peptides and is a principal therapeutic target in Alzheimer's disease. Both preclinical and clinical studies have demonstrated that inhibition of γ-secretase is associated with prohibitive side effects due to suppression of Notch processing and signaling. Potentially safer are γ-secretase modulators (GSMs), which are small molecules that selectively lower generation of the highly amyloidogenic Aβ42 peptides but spare Notch processing. GSMs with nanomolar potency and favorable pharmacological properties have been described, but the molecular mechanism of GSMs remains uncertain an…

CellsProtein subunitDrug Evaluation PreclinicalNotch signaling pathwaylcsh:MedicineCHO CellsBiochemistryModels BiologicalPresenilinInhibitory Concentration 50CricetulusCricetinaeAmyloid precursor proteinAnimalsHumansMolecular Targeted TherapyEnzyme InhibitorsMode of actionlcsh:ScienceBiologyCells CulturedMultidisciplinarybiologyEnzyme ClassesChemistryAnti-Inflammatory Agents Non-SteroidalHEK 293 cellslcsh:RChemical ReactionsPresenilinsProteinsSmall moleculeEnzymesChemistryHEK293 CellsNeurologyBiochemistrybiology.proteinMedicineDementialcsh:QAmyloid Precursor Protein SecretasesAmyloid precursor protein secretaseResearch ArticlePLoS ONE
researchProduct

Bioactive pyrrole-based compounds with target selectivity

2020

The discovery of novel synthetic compounds with drug-like properties is an ongoing challenge in medicinal chemistry. Natural products have inspired the synthesis of compounds for pharmaceutical application, most of which are based on N-heterocyclic motifs. Among these, the pyrrole ring is one of the most explored heterocycles in drug discovery programs for several therapeutic areas, confirmed by the high number of pyrrole-based drugs reaching the market. In the present review, we focused on pyrrole and its hetero-fused derivatives with anticancer, antimicrobial, and antiviral activities, reported in the literature between 2015 and 2019, for which a specific target was identified, being resp…

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antineoplastic AgentsReview ArticlePyrroleAntiviral Agentschemistry.chemical_compoundAnti-Infective AgentsDrug DiscoveryHumansPyrrolesMolecular Targeted TherapyAntiviralTargeted compoundsPyrrolePharmacologyDrug discoveryChemistryOrganic ChemistryCOVID-19Biological activityGeneral MedicineAntimicrobialSettore CHIM/08 - Chimica FarmaceuticaCombinatorial chemistryAnticancerDrug DesignAntimicrobialPharmacophoreSelectivityEuropean Journal of Medicinal Chemistry
researchProduct

Multivariate analysis in the identification of biological targets for designed molecular structures: The BIOTA protocol

2013

In this work the new protocol BIOlogical Target Assignation (BIOTA) for the prediction of the biological target from molecular structures is proposed. BIOTA is based on the Principal Components Analysis (PCA) application on a matrix of ligands versus molecular descriptors. The application of BIOTA could allow to hypothesize the mechanism of action of a candidate drug prior to its biological evaluation or to repurpose old drugs. The protocol can be fine-tuned by choosing opportune targets (biological or not) and molecular descriptors, and it can be useful in every fields in with it is possible to collect set of compounds with known properties. The robustness of the protocol depends from diff…

CorrectnessComputational biologyBiologyBioinformaticsMolecular descriptorDrug DiscoveryHumansHSP90 Heat-Shock ProteinsMolecular Targeted TherapyPharmacologyPrincipal Component AnalysisBiological dataintegumentary systemBIOTA protocol Biological target Inhibitors PCA Drugs repurposingfungiOrganic ChemistryDrug RepositioningRobustness (evolution)BiotaGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaBiological targetSettore CHIM/03 - Chimica Generale E InorganicaMultivariate AnalysisPrincipal component analysisIdentification (biology)
researchProduct

Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target in LKB1 Mutant Lung Cancer

2013

Abstract The LKB1/STK11 tumor suppressor encodes a serine/threonine kinase, which coordinates cell growth, polarity, motility, and metabolism. In non–small cell lung carcinoma, LKB1 is somatically inactivated in 25% to 30% of cases, often concurrently with activating KRAS mutations. Here, we used an integrative approach to define novel therapeutic targets in KRAS-driven LKB1-mutant lung cancers. High-throughput RNA interference screens in lung cancer cell lines from genetically engineered mouse models driven by activated KRAS with or without coincident Lkb1 deletion led to the identification of Dtymk, encoding deoxythymidylate kinase (DTYMK), which catalyzes dTTP biosynthesis, as synthetica…

DNA Replicationcongenital hereditary and neonatal diseases and abnormalitiesLung NeoplasmsMutantSTK11BiologyAMP-Activated Protein KinasesProtein Serine-Threonine Kinasesmedicine.disease_causeArticleProto-Oncogene Proteins p21(ras)MiceDeoxythymidylate kinaseAMP-Activated Protein Kinase KinasesRNA interferenceCell Line TumorCarcinoma Non-Small-Cell LungmedicineMetabolomicsThymine NucleotidesAnimalsHumansMolecular Targeted TherapyLung cancerskin and connective tissue diseasesCell DeathModels GeneticKinaseCell growthGenomicsmedicine.diseaseMolecular biologyHigh-Throughput Screening AssaysOncologyGene Knockdown TechniquesCancer researchRNA InterferenceKRASNucleoside-Phosphate KinaseDNA Damage
researchProduct

Imaging to study solid tumour origin and progression: lessons from research and clinical oncology

2017

Biomedical imaging in recent decades has clarified our understanding of normal and pathological cellular processes in vivo. In particular, this approach recently provided insights into processes occurring at a molecular or genetic level rather than at the anatomical level. The evolution of this discipline by engineering have led to its integration into biomedical research to (1) increase sensitivity and resolution imaging and to (2) improve tissue and cell specificity. Currently, imaging approaches are used in three different biomedical areas: (a) identification of cellular processes in physiological and disease state; (b) in vivo single-cell imaging; and (c) identification of new prognosti…

Diagnostic Imaging0301 basic medicineOncologymedicine.medical_specialtyPathologyeducationImmunologyBiologyMedical OncologyMultimodal Imaging03 medical and health sciences0302 clinical medicineCancer stem cellNeoplasmsInternal medicinemedicineAnimalsHumansImmunology and AllergyMolecular Targeted TherapySolid tumourClinical OncologyResearchOptical ImagingCell BiologyImaging cell biology cancer stem cellsMolecular ImagingCell Transformation Neoplastic030104 developmental biology030220 oncology & carcinogenesisDisease ProgressionNeoplastic Stem Cells
researchProduct

Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View

2020

Multidrug resistance (MDR), of the innate and acquired types, is one of major problems in treating tumor diseases with a good chance of success. In this review, we examine the key role of nuclear factor-kappa B (NF-κB) to induce MDR in three tumor models characterized precisely by innate or acquired MDR, in particular triple negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML). We also present different pharmacological approaches that our group have employed to reduce the expression/activation of this transcriptional factor and thus to restore chemo-sensitivity. Finally, we examine the latest scientific evidence found by other groups, the most sign…

Drug targetAntineoplastic AgentsReviewCatalysisNF-κBdrug targetlcsh:ChemistryInorganic Chemistrychemistry.chemical_compoundNeoplasmsMDRmedicineBiomarkers TumorcancerAnimalsHumansMolecular Targeted TherapyPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyTriple-negative breast cancerbusiness.industryOrganic ChemistryNF-kappa BCancerMyeloid leukemiaNF-κBGeneral Medicinemedicine.diseaseComputer Science ApplicationsMultiple drug resistanceClinical trialCell Transformation Neoplasticlcsh:Biology (General)lcsh:QD1-999chemistryDrug Resistance NeoplasmHepatocellular carcinomaCancer researchSettore BIO/14 - FarmacologiaDisease SusceptibilitybusinessInternational Journal of Molecular Sciences
researchProduct

Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature

2015

Despite massive investments in drug research and development, the significant decline in the number of new drugs approved or translated to clinical use raises the question, whether single targeted drug discovery is the right approach. To combat complex systemic diseases that harbour robust biological networks such as cancer, single target intervention is proved to be ineffective. In such cases, network pharmacology approaches are highly useful, because they differ from conventional drug discovery by addressing the ability of drugs to target numerous proteins or networks involved in a disease. Pleiotropic natural products are one of the promising strategies due to their multi-targeting and d…

EpigenomicsProteomics0301 basic medicineDrugmedia_common.quotation_subjectSystems biologyGene regulatory networkSynthetic lethalityDiseaseComputational biologyBiologyPharmacology03 medical and health sciencesNeoplasmsDrug DiscoveryBiomarkers TumormedicineAnimalsHumansMetabolomicsGene Regulatory NetworksMolecular Targeted TherapyProtein Interaction Mapsmedia_commonPharmacologyPlants MedicinalDrug discoveryGene Expression ProfilingSystems BiologyCancermedicine.diseaseAntineoplastic Agents PhytogenicGene Expression Regulation Neoplastic030104 developmental biologyBiological networkPhytotherapySignal TransductionPharmacological Research
researchProduct